

# Pfizer EHA2022 Hybrid Congress

Thursday 9 June, 2022 | 08:00–09:30 (CEST)

Hall Strauss 1+2, Messe Wien Exhibition  
& Congress Center, Vienna, Austria

Remotely in Virtual Room 6

## Navigating the challenge of invasive mould disease (IMD) diagnosis and management: real-world case studies



Pfizer is proud to support the 27<sup>th</sup> congress of the European Haematology Association. This hybrid symposium will explore IMD in the haematology unit, drawing from real-life clinical experiences from the COVID-19 pandemic. The challenges of diagnosing IMD, the latest management approaches and current guidelines on IMD management in the haematology unit will be summarised. Treatment recommendations for invasive mould infections in haematology patients will also be discussed.

### Agenda

**Chair: Elizabeth de Kort (Netherlands)**

|   |   |   |
|---|---|---|
| <b>08:00–08:05</b><br>Live (5 min)            | » | <b>Welcome and introduction</b><br><i>Chair: Elizabeth de Kort (Netherlands)</i>  |
| <b>08:05–08:25</b><br>Pre-recorded<br>(20min) | » | <b>Highlighting the challenges of diagnosing IMD<br/>in the haematology unit: a case study</b><br><i>Toine Mercier (Belgium)</i>                  |
| <b>08:25–08:45</b><br>Live (20 min)           | » | <b>How to choose the best approach for the management of IMD<br/>in the haematology unit</b><br><i>Elizabeth de Kort (Netherlands)</i>            |
| <b>08:45–09:05</b><br>Live (20 min)           | » | <b>Managing patients at risk of viral-associated aspergillosis<br/>in the haematology unit: a case study</b><br><i>Carol Garcia-Vidal (Spain)</i> |
| <b>09:05–09:25</b><br>Live (20 min)           | » | <b>Discussion and Q&amp;A</b><br><i>All faculty</i>   |
| <b>09:25–09:30</b><br>Live (5 min)            | » | <b>Summary and closing remarks</b><br><i>Chair: Elizabeth de Kort (Netherlands)</i>   |



Before prescribing Pfizer medicinal products, please refer to the full Summary of Product Characteristics (SmPCs).  
Please refer to your local authorities concerning reimbursement status. Medicinal products subject to medical prescription.  
For healthcare professionals only. Pfizer Corporation Austria Gesellschaft M.B.H. Floridsdorfer Hauptstraße 1, 1210 Wien, Austria.  
<https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba> | <https://www.pfizermed.at/>

PP-CRB-GLB-0951 | Date of Preparation: May 2022  
© 2022 Pfizer Inc. All rights reserved.